Spina E, Avenoso A, Campo G M, Caputi A P, Perucca E
Institute of Pharmacology, University of Messina, Italy.
Ther Drug Monit. 1994 Aug;16(4):432-4. doi: 10.1097/00007691-199408000-00017.
The effect of cholestyramine (4 g t.i.d. for 5 days) on the steady-state plasma concentrations of imipramine and desipramine was assessed in six depressed patients receiving chronic treatment with imipramine (75-150 mg/day). Compared with baseline, cholestyramine treatment was associated with an average 23% decrease in plasma imipramine levels [from 211 +/- 95 to 159 +/- 67 nmol/L, (mean +/- SD), p < 0.05], whereas desipramine levels decreased only marginally. These data suggest that administration of cholestyramine at therapeutic doses impairs the gastrointestinal absorption of concurrently prescribed imipramine by an extent that is potentially clinically significant.
在6名接受丙咪嗪（75 - 150毫克/天）长期治疗的抑郁症患者中，评估了消胆胺（每日3次，每次4克，共5天）对丙咪嗪和地昔帕明稳态血药浓度的影响。与基线相比，消胆胺治疗使血浆丙咪嗪水平平均降低了23%[从211±95降至159±67纳摩尔/升，（均值±标准差），p<0.05]，而地昔帕明水平仅略有下降。这些数据表明，治疗剂量的消胆胺给药会损害同时开具的丙咪嗪的胃肠道吸收，其程度可能具有临床意义。
